Picture of Surface Oncology logo

SURF — Surface Oncology News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall Cap

Surface Oncology Inc expected to post a loss of 47 cents a share - Earnings Preview

* Surface Oncology Inc  SURF.OQ   SURF.O  is expected
to show a
fall in quarterly revenue when it reports  results on November 2
(estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 79.6% decrease in revenue to $80 thousand from $392 thousand
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Surface Oncology
Inc is
for a loss of 47 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Surface
Oncology
Inc is $12​, above​ its last closing price of $1.26. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.47       -0.46      -0.46     Met     -0.4
 Mar. 31 2022  -0.28       -0.28      0.13      Beat    145.6
 Dec. 31 2021  -0.15       -0.15      -0.52     Missed  -242.8
                                                        ​
 Sep. 30 2021  -0.40       -0.40      -0.44     Missed  -9.1
 ​​Jun.        -0.35       -0.35      -0.44     Missed  -24.5
 30 2021                                                
 Mar. 31 2021  -0.41       -0.41      -0.37     Beat    9.3​
 Dec. 31 2020  0.41        0.22       1.56      Beat    615.6
 Sep. 30 2020  -0.39       -0.39      -0.39     Met     1
 This summary was machine generated October 31 at 14:37 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Surface Oncology

See all news